Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

The seasonal timing of when infants receive the new respiratory syncytial virus ... that research. Vaccines and medications are still studied after FDA approval to track their effectiveness ...

Infants aged 2 years or younger, pregnant women and adults aged older than 50 years qualify for an FDA-approved RSV vaccine ... us because it’s showing the effectiveness of the monoclonal ...

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

The monoclonal antibody nirsevimab, designed to mimic natural antibodies, significantly reduces severe RSV-related ...

Pfizer has bolstered the evidence behind its respiratory syncytial virus (RSV ... in order to protect their babies after birth found that the vaccine had efficacy of 81.8% in preventing lower ...

Twelve more US children have died of influenza, surpassing the previous high for a flu season outside of a pandemic year, the ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

A three-year study has found robust evidence that one particular vaccine for respiratory syncytial virus (RSV) offers older adults long-term protection against the infection, even if efficacy ...

A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of the virus. A booster dose one year after the initial shot failed to do ...